Using glyco-engineering to produce therapeutic proteins

Area of Science:

• Biopharmaceutical Development
• Glycobiology
• Protein Engineering

Background:

• Glycans are crucial for biopharmaceutical properties like efficacy and half-life.
• Existing expression systems often yield heterogeneous or non-human glycans, leading to adverse effects.
• Glyco-engineering offers a solution to these limitations in biomanufacturing.

Purpose of the Study:

• To review recent advancements in glyco-engineering strategies for recombinant protein expression.
• To focus on in vivo systems for producing glycoproteins with controlled glycosylation.
• To highlight methods for achieving homogeneous N- and O-linked glycans.

Main Methods:

• Review of glyco-engineering techniques applied to various expression systems (mammalian cells, yeast, plants).
• Analysis of strategies for modifying glycosylation pathways in vivo.
• Focus on achieving defined glycan compositions.

Main Results:

• Glyco-engineering is a key strategy for improving biopharmaceutical quality.
• Controlling glycan heterogeneity simplifies production and reduces variability.
• Advances enable the development of glycoprotein therapeutics with tailored functions.

Conclusions:

• Glyco-engineering is essential for optimizing biopharmaceuticals.
• Understanding and controlling glycosylation is critical for consistent manufacturing.
• Future technological progress will lead to novel glycoprotein therapeutics with customized functionalities.